Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as ALXN2050 MR Prototype Tablet
ALXN2050 Prototype · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Cohort 1 | EXPERIMENTAL | Regimen A: Participants will receive Dose B (3 x Dose A) ALXN2050 IR Tablet orally under fasted conditions. Regimen B: Participants will receive Dose C ALXN2050 MR Prototype Tablet orally under fasted conditions. Optional Regimens C, D, E, and F |
| Cohort 2 | EXPERIMENTAL | Regimen G: Participants will receive Dose B (3 x Dose A) ALXN2050 IR Tablet orally under fasted conditions. Regimen H: Participants will receive Dose C ALXN2050 MR Prototype Mini-Tablet orally under fasted conditions. Optional Regimens: I, J, K, and L |
| Name | Type | Description |
|---|---|---|
| ALXN2050 MR Prototype Tablet | DRUG | Participants will receive various doses of the MR Prototype Tablet orally. |
| ALXN2050 Immediate Release (IR) Tablet | DRUG | Participants will receive a single dose IR (ALXN2050 Film Coated Tablet) tablet orally. |
| ALXN2050 MR Prototype Mini-Tablet | DRUG | Participants will receive various doses of the MR Prototype Mini-Tablet orally. |
Inclusion Criteria: * Healthy males or non-pregnant, non-lactating healthy females. * Participants who are overtly healthy as determined by medical evaluation including medical history, physical or neurological examination, vital signs, 12-lead ECG, screening clinical laboratory profiles (hematolog...
ALXN2050 Prototype is an investigational small molecule developed by AstraZeneca PLC. It is a modified release prototype tablet formulation studied in healthy adult participants, not in patients with a specific disease. The program is in Phase 1 clinical development, and no therapeutic indication has been disclosed for this prototype formulation.
ALXN2050 Prototype is being developed by AstraZeneca PLC, which trades on the Nasdaq under the ticker AZN. AstraZeneca is the sponsor of the clinical study evaluating this modified release prototype tablet formulation.
ALXN2050 Prototype is in Phase 1 clinical development. It is an investigational product and has not been approved by the FDA or any other regulatory authority. The single Phase 1 study of this prototype has been completed.
ALXN2050 Prototype has been studied in one Phase 1 trial, NCT05780645, titled a study to investigate the pharmacokinetic profile of ALXN2050 modified release prototype formulations and immediate release reference tablet in healthy adult participants. The trial enrolled 80 healthy adults in the United Kingdom and is now completed.
Yes. ALXN2050 Prototype is also known as ALXN2050 MR Prototype Tablet. Both names refer to the same modified release prototype tablet formulation developed by AstraZeneca PLC, so readers searching under either name are looking at the same investigational asset.
Trial NCT05780645 was a controlled, randomized Phase 1 study of ALXN2050 modified release prototype formulations and an immediate release reference tablet in healthy adult participants. It enrolled 80 participants of all sexes, aged 18 years and older, at sites in the United Kingdom, and it has been completed.